AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18525041
Drug: Aliskiren (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150 mg daily for 3 months, then 300 mg daily for 3 months)
Trial: 12025250
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine (12.5 mg)
Trial: 12025250
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine (12.5 mg)
Trial: 10496549
Drug: Age and
RxNorm normalized name: wound drainage and fistula management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age and number of medications
Trial: 2140554
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion (1.5 micrograms/Kg/min for 60 min)
Trial: 7004257
Drug: Self-administered intravenous
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intravenous pethidine (0.25 mg/kg available at 10-min intervals)
Trial: 7004257
Drug: Intramuscular pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine (150 mg, repeated if necessary)
Trial: 26863353
Drug: Caplacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caplacizumab (10 mg daily)
Trial: 25002290
Drug: Levothyroxine (L‐T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (L‐T4) adjunctive treatment
Trial: 11465523
Drug: Doxepin (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (25-50 mg)
Trial: 9604124
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg artemisinin
Trial: 9604124
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg artemisinin
Trial: 9604124
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg artemisinin
Trial: 9604124
Drug: Artemisinin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin (all doses)
Trial: 8067230
Drug: Morphine/bupivacaine (MB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine/bupivacaine (MB) - morphine at 0.2 mg.h‐1 and bupivacaine at 10 mg.h‐1 for the first 24 h, then 5 mg.h‐1 for the second 24 h
Trial: 8067230
Drug: Fentanyl/bupivacaine (FB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl/bupivacaine (FB) - fentanyl at 20 micrograms.h‐1 and bupivacaine at 10 mg.h‐1 for the first 24 h, then 5 mg.h‐1 for the second 24 h
Trial: 28454801
Drug: Anacetrapib 100mg
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib 100mg daily
Trial: 23727422
Drug: HBsAg-1018 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg-1018 (20 mcg rHBsAg + 3000 mcg 1018, a toll‐like receptor 9 agonist) given at 0, 4, and 24 weeks
Trial: 23727422
Drug: HBsAg-Eng (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBsAg-Eng (4 double-doses of 2×20 mcg rHBsAg + 500 mcg alum given at 0, 4, 8, and 24 weeks)
Trial: 19129506
Drug: Antiplatelet medications
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet medications at ICH onset
Trial: 9088076
Drug: Intravenous Epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Epoetin alfa (300 IU/kg twice weekly for 3 weeks)
Trial: 9088076
Drug: Subcutaneous Epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Epoetin alfa (100 IU/kg twice weekly for 3 weeks plus an i.v. bolus of 200 IU/kg at the first visit)
Trial: 3742316
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A - ten per cent methohexitone, 25 mg X kg‐1 (n = 20)
Trial: 3742316
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B - ten per cent methohexitone, 15 mg X kg‐1 (n = 20)
Trial: 3742316
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C - one per cent methohexitone, 15 mg X kg‐1 (n = 20)
Trial: 3742316
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A - ten per cent methohexitone, 25 mg X kg‐1
Trial: 3742316
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C - one per cent methohexitone, 15 mg X kg‐1
Trial: 29550045
Drug: Ticagrelor (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (90 mg twice daily for 6 months) + Aspirin (81 mg for 6 months)
Trial: 29550045
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg once daily for 1 month) + Aspirin (81 mg for 6 months)
Trial: 19936713
Drug: Control day
RxNorm normalized name: Avobenzone 30 mg in 1 mL / Octinoxate 75 mg in 1 mL TOPICAL LOTION [Oil-Control Day SPF 15]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control day (air inhalation)
Trial: 15653003
Drug: 17beta-estradiol and
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17beta-estradiol and levonorgestrel (both doses)
Trial: 10402244
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) as a single agent
Trial: 10402244
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) in combination with dacarbazine
Trial: 10402244
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) in combination with various cytotoxic agents
Trial: 10402244
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) combined with cisplatin at high doses
Trial: 1661657
Drug: L-arginine free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine free base (5 mumol/min)
Trial: 1661657
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine hydrochloride (5 mumol/min)
Trial: 1661657
Drug: L-arginine free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine free base (160 mumol/min)
Trial: 1661657
Drug: L-arginine hydrochloride
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine hydrochloride (160 mumol/min)
Trial: 6136292
Drug: Clobazam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clobazam (10 mg twice a day)
Trial: 6136292
Drug: Lorazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1 mg twice a day)
Trial: 3902533
Drug: Flunisolide inhalation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide inhalation, 500 mcg twice daily
Trial: 3902533
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate inhaler, 100 mcg four times daily
Trial: 26987975
Drug: V158866 (5-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V158866 (5-300 mg single doses; 50-500 mg repeated doses)
Trial: 26987975
Drug: V158866 (300-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V158866 (300-500 mg/day)
Trial: 23494104
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LLLT or ozone therapy)
Trial: 19793142
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - enoxaparin 1 mg/kg bd
Trial: 16901550
Drug: 1-deamino 8-D-arginine
RxNorm normalized name: 1-deamino-8-D-arginine vasopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-deamino 8-D-arginine vasopressin (DDAVP) spray
Trial: 26599707
Drug: Diesel exhaust
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diesel exhaust (200 μg/m(3) PM2.5)
Trial: 22595974
Drug: Oral absorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral absorbable fat-soluble vitamin formulation (OAFSV)
Trial: 19940231
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Rd (single dose)
Trial: 19940231
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg Rd (single dose)
Trial: 19940231
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg Rd (single dose)
Trial: 19940231
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Rd (multiple dose)
Trial: 18567166
Drug: Metronidazole plus
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole plus Amoxicillin
Trial: 7782581
Drug: CO2 laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 laser treatment for cervical intraepithelial neoplasia
Trial: 321991
Drug: Dimethothiazine, 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethothiazine, 60 mg/day for 2 to 3-4 months
Trial: 23168581
Drug: ARA 290
RxNorm normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARA 290 (2 mg, intravenous, three times weekly for 4 weeks)
Trial: 20164296
Drug: Teriparatide 40
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide 40 microg sc daily
Trial: 18478937
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose thymopentin (10 mg/d) combined with trans-artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5‐Fu 750 mg, CF 300 mg and lipiodol 20 ml.
Trial: 18478937
Drug: Trans-artery chemoembolization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans-artery chemoembolization (TACE) with oxaliplatin 150 mg, pharmorubicin 50 mg, 5‐Fu 750 mg, CF 300 mg and lipiodol 20 ml.
Trial: 18478937
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose thymopentin (10 mg/d) combined with TACE.
Trial: 12152996
Drug: Gemcitabine 1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1250 mg/mq (days 1, 8 and 15) as a single agent for 3 monthly courses
Trial: 12152996
Drug: Gemcitabine 1000
RxNorm normalized name: gemcitabine 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1000 mg/mq (days 1, 8 and 15) plus cisplatin 80 mg/mq (day 1)
Trial: 12152996
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to treatment failure (TTF)
Trial: 10622647
Drug: Rocuronium (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (both doses)
Trial: 8622102
Drug: Isepamicin 8
RxNorm normalized name: isepamicin
DrugBank: Isepamicin (DB13540)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isepamicin 8 or 15 mg/kg once daily
Trial: 6893580
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg sublingual molsidomine
Trial: 24383496
Drug: Antibiotic-impregnated VPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic-impregnated VPS
Trial: 21967645
Drug: Ticagrelor 270
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 270 mg (3×90 mg tablets) after a 10-h overnight fast
Trial: 21967645
Drug: Ticagrelor 270
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor 270 mg (3×90 mg tablets) after a standard high-fat, high-calorie breakfast
Trial: 19296870
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 supplementation (50 microg or 2000 IU daily for 12 weeks)
Trial: 17469042
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg per day)
Trial: 11989392
Drug: Exogenous hyaluronan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous hyaluronan administration
Trial: 1399475
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous cannulas
Trial: 3540879
Drug: Propoxyphene HCl
RxNorm normalized name: propoxyphene HCl
DrugBank: Dextropropoxyphene (DB00647)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propoxyphene HCl 65 mg
Trial: 3540879
Drug: Aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 650 mg with codeine 60 mg
Trial: 24641522
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate (CP) 0.05% ointment
Trial: 24641522
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MMF) 0.1% ointment
Trial: 22581482
Drug: Worry exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Worry exposure therapy (n = 29)
Trial: 22581482
Drug: Applied relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied relaxation therapy (n = 27)
Trial: 22581482
Drug: Post therapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post therapy (immediate outcome)
Trial: 17653011
Drug: Ulinastatin (1000000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (1000000 U total dose)
Trial: 2154314
Drug: Brachytherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brachytherapy alone or with external beam radiation therapy or surgery
Trial: 2154314
Drug: Intraoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiation therapy
Trial: 2154314
Drug: Hyperthermia with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermia with radiation therapy
Trial: 2154314
Drug: Infusional (intravenous)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusional (intravenous) chemotherapy with radiation therapy
Trial: 2154314
Drug: Intraarterial monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial monoclonal antibodies with radionuclides and intraarterial chemotherapy with radiation therapy
Trial: 7357805
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% ophthalmic solution (2 drops to each eye with precautions)
Trial: 7357805
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% ophthalmic solution (1 drop to each eye with no special precautions)
Trial: 7357805
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% ophthalmic solution
Trial: 22729611
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus multitargeted antiangiogenic TKI
Trial: 14679127
Drug: Topotecan (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.5 mg/m(2)/day for 5 days)
Trial: 14679127
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m(2)/day as a 3‐h infusion every 21 days)
Trial: 11689808
Drug: Nitroglycerin (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin (bolus injection of 2 mg)
Trial: 9039301
Drug: Calcipotriol cream
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol cream (50 micrograms/g)
Trial: 9039301
Drug: Betamethasone 17-valerate
RxNorm normalized name: Cortisol 17-valerate
DrugBank: Hydrocortisone valerate (DB14544)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone 17-valerate cream (1 mg/g)
Trial: 15037415
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive containing 3 mg of drospirenone + 30 microg of ethinyl estradiol (DRSP + EE)
Trial: 11722416
Drug: Serum transferrin
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum transferrin receptor (sTfR) and TfR-Index
Trial: 29073802
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (ST)
Trial: 22276506
Drug: QRHX decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QRHX decoction (composed of Huangbai, Chishao, Bixie, Danshen, Ezhu, Qingfengteng, raw Huangqi, Jinyinhua, Tufuling, Wugong, Fengfang, raw Yiyiren, cooked with water as 400 ml liquid)
Trial: 19590482
Drug: Steroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid treatment (prednisolone 20 mg daily for 2 weeks followed by 10 mg daily for 2 weeks)
Trial: 12632273
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with biweekly FOLFOX regimen (FOL: 500 mg/m2, F: 2000 mg/m2 for 2 days, OX: 85 mg/m2)
Trial: 11108443
Drug: Local nasal
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local nasal immunotherapy (LNIT) with powder extract of Graminaceae or Parietaria pollens
Trial: 11108443
Drug: Symptomatic pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic pharmacological treatment only (Control)
Trial: 8601647
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg daily (21 patients)
Trial: 8601647
Drug: Terbinafine 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 500 mg daily for 1 week every month (21 patients)
Trial: 8601647
Drug: Itraconazole 400
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole 400 mg daily for 1 week every month (21 patients)
Trial: 6463598
Drug: Thiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide (50 mg hydrochlorthiazide)
Trial: 30802196
Drug: Intravenous sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous sufentanil (1 μg/kg) and midazolam (0.2 mg/kg) (Group SM)
Trial: 28619016
Drug: Endoscopic mask
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoscopic mask oxygen-providing (3 L/min during intubation)
Trial: 26974018
Drug: Rocuronium 1
RxNorm normalized name: rocuronium 10 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 1 mg/kg reversed with Sugammadex 2-4 mg/kg
Trial: 26974018
Drug: Suxamethonium 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium 1 mg/kg for induction, Rocuronium 0.3 mg/kg for maintenance, Neostigmine 0.03 mg/kg for reversal
Trial: 23253641
Drug: Computerized cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized cognitive behavioural therapy (cCBT)
Trial: 23253641
Drug: Computer-administered attention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-administered attention placebo program with psychoeducational content (CPE)
Trial: 19222417
Drug: No acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No acid regurgitation or epigastric pain pre-treatment
Trial: 17470584
Drug: Daily Record
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Record of Severity of Problems (DRSP) scores using the standard method
Trial: 17470584
Drug: Daily Record
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Record of Severity of Problems (DRSP) scores using the alternative method
Trial: 11488789
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (ranitidine, colloidal bismuth subcitrate, metronidazole, and tetracycline)
Trial: 7974072
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg trospectomycin sulfate i.m.
Trial: 7974072
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg ceftriaxone i.m.
Trial: 30884170
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg s.c.
Trial: 30884170
Drug: Anakinra 150
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 150 mg s.c.
Trial: 30884170
Drug: Anakinra 300
RxNorm normalized name: ANAKINRA
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Anakinra 300 mg s.c.
Trial: 30884170
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg i.v.
Trial: 28749480
Drug: Caffeine citrate
RxNorm normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine citrate at 10 mg kg‐1 day‐1, increased to 14 or 20 mg kg‐1 day‐1 BID at 36 weeks PMA